Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 85.91% is 205% above its 5-year average of 28.16%, near the high end of its 5-year range (0.00%–100.00%).
9.73% above its 12-month average of 78.29%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
85.91%
GROSS MARGIN AVG TTM
78.29%
GROSS MARGIN AVG 3Y
45.50%
GROSS MARGIN AVG 5Y
28.16%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+9.73%
CURRENT VS 3Y AVG
+88.83%
CURRENT VS 5Y AVG
+205.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+107.61%
vs the sector median at left
Prelude Therapeutics Incorporated
Market Cap
$214.64M
Gross Margin
85.91%
TTM Avg
78.29%
3Y Avg
45.50%
5Y Avg
28.16%
Market Cap
$214.19M
Gross Margin
87.24%
TTM Avg
79.57%
3Y Avg
65.64%
5Y Avg
63.99%
Market Cap
$213.84M
Gross Margin
64.24%
TTM Avg
63.06%
3Y Avg
61.57%
5Y Avg
61.22%
Market Cap
$213.43M
Gross Margin
-31952.78%
TTM Avg
-15926.39%
3Y Avg
-7913.19%
5Y Avg
-5242.13%
Market Cap
$210.25M
Gross Margin
83.89%
TTM Avg
91.94%
3Y Avg
70.97%
5Y Avg
47.31%
Market Cap
$222.36M
Gross Margin
94.68%
TTM Avg
99.69%
3Y Avg
74.84%
5Y Avg
66.56%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $214.64M | 85.91% | 78.29% | 45.50% | 28.16% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $214.19M | 87.24% | 79.57% | 65.64% | 63.99% |
| Niagen Bioscience Inc (NAGE)vs › | $213.84M | 64.24% | 63.06% | 61.57% | 61.22% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.43M | -31952.78% | -15926.39% | -7913.19% | -5242.13% |
| Compugen Ltd. (CGEN)vs › | $211.37M | 86.89% | 79.42% | 84.96% | 87.58% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.25M | 83.89% | 91.94% | 70.97% | 47.31% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.73M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.55M | 31.38% | 30.34% | 28.84% | 29.64% |
| Keros Therapeutics, Inc. (KROS)vs › | $222.36M | 94.68% | 99.69% | 74.84% | 66.56% |
| Profound Medical Corp. (PROF)vs › | $222.39M | 71.79% | 68.33% | 60.69% | 55.54% |
Gross Margin
85.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 91.46% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
